Drugs.com - Clinical Trials

Alligator Bioscience Receives FDA Endorsement of Mitazalimab Phase 3 Dose for Pancreatic Cancer

Lund, Sweden – 13 June 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing tumor-directed immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has...

Jun 14, 2025 - 03:00
 0
Alligator Bioscience Receives FDA Endorsement of Mitazalimab Phase 3 Dose for Pancreatic Cancer
Lund, Sweden – 13 June 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing tumor-directed immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has...
Read More

Tags:

Previous Article

Accor opens TRIBE Budapest Airport

Next Article

Cantargia's Nadunolimab Antibody Awarded Fast Track Designation by FDA

Related Posts

Cellenkos Announces US FDA Orphan Drug Designation Granted to CK0801 (Allogeneic Cord Blood derived T regulatory Cell Product) for Treatment of Aplastic Anemia

Cellenkos Announces US FDA Orphan Drug Designation Gran...

May 12, 2025  0

Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis

Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Des...

Jun 3, 2025  0

Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint

Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for...

May 28, 2025  0